Rankings
▼
Calendar
ALKS Q2 2018 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena
ALKS
Alkermes plc
$5B
Q2 2018 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$305M
+39.2% YoY
Gross Profit
$261M
85.7% margin
Operating Income
-$102,000
-0.0% margin
Net Income
-$33M
-10.7% margin
EPS (Diluted)
$-0.21
QoQ Revenue Growth
+35.3%
Cash Flow
Operating Cash Flow
$32M
Free Cash Flow
$15M
Stock-Based Comp.
$31M
Balance Sheet
Total Assets
$1.8B
Total Liabilities
$593M
Stockholders' Equity
$1.2B
Cash & Equivalents
$156M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$305M
$219M
+39.2%
Gross Profit
$261M
$179M
+45.9%
Operating Income
-$102,000
-$45M
+99.8%
Net Income
-$33M
-$43M
+24.1%
Revenue Segments
Vivitrol
$76M
69%
Aristada
$34M
31%
← FY 2018
All Quarters
Q3 2018 →